Literature DB >> 35711192

Commentary: When to go "all in".

Jason W Greenberg1, David L S Morales1.   

Abstract

Entities:  

Year:  2021        PMID: 35711192      PMCID: PMC9195610          DOI: 10.1016/j.xjtc.2021.09.044

Source DB:  PubMed          Journal:  JTCVS Tech        ISSN: 2666-2507


× No keyword cloud information.
Jason W. Greenberg, MD (left), and David L. S. Morales, MD (right) High-risk univentricular congenital heart disease patients are sometimes best served by upfront commitment to transplant and bridging with a ventricular assist device rather than staged palliation. See Article page 194. Cardiac surgery is a specialty of “big” decisions. Bleiweis and colleagues report their algorithms for the surgical management of neonates and infants with failing univentricular congenital heart disease, their surgical technique for “hybrid” palliation with ventricular assist device (VAD) implantation, and results from their institutional experience thereof. The algorithm and surgical techniques highlighted—while comprehensive and an interesting contribution to the literature—are not wholly novel, nor is the concept of bridging to transplant with VAD complex univentricular patients. The real contribution for which the authors should be applauded is their discussion of early commitment to VAD implantation and listing for transplant in the most challenging, high-risk patients. These are the patients with whom we are all familiar and recognize to be high-risk for single-ventricle palliations: the patient with hypoplastic left heart syndrome and severe tricuspid regurgitation, those with ventricular dysfunction from birth, and those with large coronary fistulae with signs of ischemia. Instead of first attempting high-risk palliation with the plan of “bailing out” to VAD and transplantation if this fails, the authors commit directly to VAD/transplantation. This strategy prevents intervening surgeries that may result in possible extracorporeal membrane oxygenation runs and/or cardiac arrest, which can significantly impact the patient's future success on VAD and ability to make it to transplant in a good clinical state. The chance of survival in those with a “salvage” compared with a “planned” VAD is substantial. When weighing options, it is important to remember that the survival post-transplant of patients who are bridged with a VAD or not are the same, and that infants actually have the best median survival of any age group—24.5 years. Although the authors report high mortality in those treated with hybrid palliation and VAD (7/15 patients, 6 of whom died on the waiting list), a convincing argument is made that sometimes this mortality rate is favorable to pursuing staged palliation against odds of success. Our group, among others, has highlighted “the reality of limping to pediatric heart transplantation.” We have advocated for early VAD implantation and consideration for transplantation in challenging patients rather than continuing to pursue palliative univentricular procedures and waiting until patients are too sick to have good waitlist or post-transplant outcomes., However, the authors do believe that patients with hypoplastic left heart syndrome who present in shock with organ insufficiency but preserved function can be palliated with bilateral pulmonary arterial banding and resuscitated to a point in which they can usually undergo a successful Norwood. Pursuing transplantation for our univentricular patients must not be viewed as a failure of single-ventricular palliation, nor should it be viewed as a last-resort, “bail out” option when such palliations fail. Sometimes, making big decisions up-front (listing for transplantation while the patient still has a favorable clinical profile) is better than taking incremental steps when the risk for long-term success is small. Sometimes, we must go “all in” and commit to primary VAD/cardiac transplantation over staged palliation for those complex single-ventricle patients for whom data have shown us their poor hand.
  3 in total

1.  The reality of limping to pediatric heart transplantation.

Authors:  Kyle W Riggs; Farhan Zafar; Angela Lorts; Clifford Chin; Roosevelt Bryant; James S Tweddell; David L S Morales
Journal:  J Thorac Cardiovasc Surg       Date:  2019-10-31       Impact factor: 5.209

Review 2.  ISHLT consensus statement for the selection and management of pediatric and congenital heart disease patients on ventricular assist devices Endorsed by the American Heart Association.

Authors:  Angela Lorts; Jennifer Conway; Martin Schweiger; Iki Adachi; Shahnawaz Amdani; Scott R Auerbach; Charlotte Barr; Mark S Bleiweis; Elizabeth D Blume; Danielle S Burstein; Ari Cedars; Sharon Chen; Melissa K Cousino-Hood; Kevin P Daly; Lara A Danziger-Isakov; Nicole Dubyk; Lucas Eastaugh; Joshua Friedland-Little; Robert Gajarski; Asif Hasan; Beth Hawkins; Aamir Jeewa; Steven J Kindel; Shigetoyo Kogaki; Jodie Lantz; Sabrina P Law; Katsuhide Maeda; Jacob Mathew; Lindsay J May; Oliver Miera; Jenna Murray; Robert A Niebler; Matthew J O'Connor; Mustafa Özbaran; David M Peng; Joseph Philip; Leigh Christopher Reardon; David N Rosenthal; Joseph Rossano; Leonardo Salazar; Kurt R Schumacher; Kathleen E Simpson; Brigitte Stiller; David L Sutcliffe; Hari Tunuguntla; Christina VanderPluym; Chet Villa; Peter D Wearden; Farhan Zafar; Daniel Zimpfer; Matthew D Zinn; Independent Reviewers David Morales; Jennifer Cowger; Holger Buchholz; Antonio Amodeo
Journal:  J Heart Lung Transplant       Date:  2021-05-20       Impact factor: 10.247

3.  The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric heart transplantation report - 2021; focus on recipient characteristics.

Authors:  Tajinder P Singh; Wida S Cherikh; Eileen Hsich; Daniel C Chambers; Michael O Harhay; Don Hayes; Kiran K Khush; Michael Perch; Luciano Potena; Aparna Sadavarte; Alice E Toll; Andreas Zuckermann; Josef Stehlik
Journal:  J Heart Lung Transplant       Date:  2021-07-31       Impact factor: 10.247

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.